Cho Hyungseok, Kim Jinho, Han Song-I, Han Ki-Ho
Department of Nano Science and Engineering Center for Nano Manufacturing, Inje University, 607 Obang-dong, Gimhae, Gyongnam, 621-749, Republic of Korea.
Biomed Microdevices. 2016 Oct;18(5):91. doi: 10.1007/s10544-016-0116-5.
CTCs are currently in the spotlight because provide comprehensive genetic information that enables monitoring of the evolution of cancer and selection of appropriate therapeutic strategies that cannot be obtained from a single-site tumor biopsy. Despite their importance, current techniques for isolating CTCs are limited in terms of their ability to yield high-quality CTCs from peripheral blood for use in profiling cancer genetic mutations by DNA sequencing technologies. This paper introduces a lateral magnetophoretic microseparator (the 'CTC-μChip') for isolating highly pure CTCs from blood, which facilitates the detection of somatic mutations in isolated CTCs. To isolate CTCs from peripheral blood, nucleated cells were first prepared by red blood cell lysis. Then, CTCs were isolated from nucleated cells within 30 min using the CTC-μChip. Analytical evaluation using 5 mL blood samples spiked with 5-50 MCF7 breast cancer cells demonstrated that the average recovery rate of the CTC-μChip was 99.08 %. The average number of residual white blood cells (WBCs) in isolated samples was 53, meaning that the WBC depletion rate is 472,000-fold (5.67 log), assuming that blood contains 5 × 10(6) WBCs per milliliter. The isolated MCF7 cells had a purity of 6.9 - 67.9 %, depending on the spiked MCF7 concentration. Using next-generation sequencing technology, heterozygous somatic mutations (PIK3CA and APC) of MCF7 cells were evaluated in the isolated samples. The results showed that somatic mutations could be detected in as few as two MCF7 cells per milliliter of blood, indicating that the CTC-μChip facilitates the detection of somatic variants in CTCs.
循环肿瘤细胞(CTCs)目前备受关注,因为它们能提供全面的基因信息,可用于监测癌症的演变以及选择合适的治疗策略,而这些信息无法从单部位肿瘤活检中获得。尽管其重要性显著,但目前用于分离CTCs的技术在从外周血中获取高质量CTCs以用于通过DNA测序技术分析癌症基因突变方面能力有限。本文介绍了一种横向磁泳微分离器(“CTC-μ芯片”),用于从血液中分离高纯度的CTCs,这有助于检测分离出的CTCs中的体细胞突变。为了从外周血中分离CTCs,首先通过红细胞裂解制备有核细胞。然后,使用CTC-μ芯片在30分钟内从有核细胞中分离出CTCs。对添加了5 - 50个MCF7乳腺癌细胞的5毫升血样进行分析评估表明,CTC-μ芯片的平均回收率为99.08%。分离样本中残留白细胞(WBCs)的平均数量为53个,这意味着白细胞清除率为472,000倍(5.67对数),假设每毫升血液中含有5×10⁶个WBCs。根据添加的MCF7浓度不同,分离出的MCF7细胞纯度为6.9% - 67.9%。使用下一代测序技术,对分离样本中的MCF7细胞杂合体细胞突变(PIK3CA和APC)进行了评估。结果表明,每毫升血液中低至两个MCF7细胞就能检测到体细胞突变,这表明CTC-μ芯片有助于检测CTCs中的体细胞变异。